MKC · DEEP VALUE BRIEFING

MCCORMICK & CO INC (MKC)

published Oct 2, 2026 · price now $44.53 · market cap $12.0B

WATCH · low confidence — the research’s call on buying at the price it saw, not advice to you.

Information only, not investment advice. Written by AI research agents from SEC filings and market data, and it can be wrong. Check the model below before relying on any of it.

Executive Briefing

McCormick appears to retain a durable branded franchise, but the investment case is not yet sufficiently verified. At $44.14, the headline 7.34 P/E implies approximately $6.01 of EPS, yet the debate’s normalized owner-earnings estimates are only $2.50–$4.20. Until that gap is reconciled to recurring free cash flow, the apparent bargain may be illusory.

The 37.9% gross margin supports continued brand and procurement strength, but weak organic volumes, 7.4% ROIC, and acquisition execution risk prevent classification as a Buffett-style wonderful business today. There is no evidence of imminent distress, so AVOID would be excessive. Conversely, the conservative value estimate of roughly $46 provides almost no margin of safety.

Retain WATCH, but replace passive waiting with explicit operating and valuation triggers. A tightly capped exploratory position may suit diversified, uncertainty-tolerant investors; it is not justified for a capital-preservation mandate.


1. Risk Judgment

The decisive risk is not the 33% share-price decline. It is paying for earnings that may not be sustainable or cash-convertible.

McCormick has several qualities associated with a durable franchise:

  • Recognized global spice, seasoning, and flavor brands
  • Recurring household and food-service demand
  • Low product obsolescence
  • Procurement, shelf-space, food-safety, and distribution advantages
  • A healthy 37.9% gross margin

Those features make permanent franchise impairment less likely than the chart suggests. However, the current evidence does not establish elite economics:

  • ROIC is only 7.4%.
  • Organic volumes remain weak.
  • Acquisition benefits are projected rather than cash-realized.
  • The reported valuation cannot be reconciled to normalized owner earnings.
  • No reliable leverage or interest-coverage data was supplied to validate post-transaction financial resilience.

A long holding period reduces risk only when the business earns attractive returns on incremental capital and the entry price is below defensible intrinsic value. Neither condition is sufficiently demonstrated yet.


2. Strongest Arguments from the Analysts

Risky Analyst: Buy before confirmation

The bullish analyst makes three credible points:

  1. The headline P/E does not need to be fully accurate for the shares to be attractive.

At $3.60–$4.20 of owner earnings, MKC would trade at approximately 12.3–10.5 times normalized cash earnings, equivalent to an 8.2%–9.5% owner-earnings yield.

  1. Weak volumes may be temporary rather than structural.

McCormick operates in a recurring, low-ticket category, while margin resilience suggests that its brands and procurement platform still possess economic value.

  1. Waiting for complete confirmation has a cost.

If volumes stabilize, synergies become visible, and debt declines, the shares may already have recovered into the $50s. A small position would preserve some participation.

These points justify close monitoring and explain why AVOID is inappropriate. They do not, however, resolve the uncertain earnings denominator.

Safe Analyst: Require cash-flow proof

The conservative analyst correctly identifies the principal underwriting problem:

  • The 7.34 P/E implies roughly $6.01 of EPS.
  • The debate’s owner-earnings range is materially lower.
  • At $2.50–$3.00 of owner earnings, MKC trades at approximately 17.7–14.7 times cash earnings.

Those lower multiples are not obviously cheap for a company with weak volumes, modest ROIC, transaction costs, and uncertain leverage. The analyst is also right that:

  • Gross-margin strength does not prove brand health if marketing or promotion has been restrained.
  • Good acquisition targets can still destroy shareholder value if purchased at excessive prices.
  • ROE of 13.8% does not override low ROIC because leverage can elevate ROE.
  • Oversold conditions and unreliable options data do not establish intrinsic value.

The weakness in this position is requiring nearly every uncertainty to be resolved before any exposure. That could cause an investor to miss a recoverable branded franchise.

Neutral Analyst: Conditional participation

The neutral position is the most balanced. It recognizes that:

  • A normal-sized purchase is not supported by the current scenario range.
  • Equal weighting of the $31, $46, and $59 values produces approximately $45.33, barely above the current price.
  • Position sizing can control portfolio risk even though it cannot improve intrinsic value.
  • Additions should depend on operating evidence, not merely a falling share price.

The proposed 0.5%–1.0% exploratory allocation is reasonable only for investors willing to accept unresolved uncertainty. It should not be confused with a validated Buffett-style investment.


3. Valuation and Margin of Safety

The valuation evidence is not yet strong enough for ADVOCATE.

Owner earnings per shareMultiple at $44.14Interpretation
$2.5017.7xUnattractive given weak growth and transaction risk
$3.0014.7xFair, but not clearly discounted
$3.6012.3xPotentially attractive
$4.2010.5xCompelling if sustainable
Implied reported EPS: $6.017.34xToo uncertain to underwrite without reconciliation

McCormick may deserve a smaller discount than a low-quality cyclical because of its category durability. But a 7.4% ROIC, weak volumes, and acquisition dependence mean it does not currently merit the narrow 10%–15% margin of safety appropriate for an elite compounder.

The supplied scenarios reinforce that conclusion:

  • Bear value: $31, approximately 30% downside
  • Conservative value: $46, approximately 4% upside
  • Favorable value: $59, approximately 34% upside

The favorable case requires owner-earnings recovery and acceptable transaction execution. The conservative case offers almost no protection. Expected value therefore depends too heavily on outcomes not yet demonstrated.


4. Permanent Versus Temporary Risks

Probably temporary or non-decisive

  • The 33% one-year share-price decline
  • Deeply oversold technical conditions
  • A single period of weak consumer demand
  • Temporary integration expenses
  • Deliberate spending that depresses near-term margins while strengthening the franchise

These should not independently break the thesis.

Potentially permanent

  • Sustained volume and market-share losses to private labels
  • Margin defense through underinvestment in brands
  • Owner earnings persistently below approximately $3.00 per share
  • Acquisitions that increase reported earnings but not free cash flow per share
  • Failure to reduce debt after the transactions
  • Post-acquisition ROIC remaining near or below 7.4%
  • Recurring “one-time” integration and restructuring adjustments
  • Deteriorating fundamentals combined with weak interest coverage

No hard-distress evidence has been supplied. That prevents an AVOID conclusion, but the absence of leverage and interest-coverage data also prevents assuming the balance sheet is unquestionably safe.


5. Refined Investor Plan

Original plan

The original plan was to keep McCormick on watch, reconcile earnings to cash flow, monitor volumes and margins, assess acquisitions through debt reduction and post-transaction ROIC, and consider approximately $39 as a more attractive price if fundamentals remained intact.

Adjusted plan

Retain that framework, with four improvements.

1. Separate investment confirmation from tactical price movement

An oversold rebound is plausible, but it is not evidence of intrinsic value. Do not upgrade the long-term thesis because the shares bounce. Technical stabilization may improve entry timing only after the cash-flow thesis becomes credible.

The options put/call ratio should receive effectively zero weight because the underlying data is thin, inconsistent, and possibly stale.

2. Use two valid entry paths

Operating-confirmation path: Consider a staged investment, even above $44, if:

  • Recurring owner earnings credibly approach or exceed $3.60 per share
  • Organic volumes stabilize over at least two reporting periods
  • Free cash flow per share grows after interest and integration costs
  • Debt declines according to a clear schedule
  • Margins hold after normal marketing and promotional spending

Valuation path: Consider a small initial position near $39 only if:

  • Cash-flow expectations have not deteriorated
  • Market share remains intact
  • Leverage and interest coverage remain acceptable
  • Acquisition costs and synergies remain within reasonable bounds

A lower price alone is not a buy signal.

3. Distinguish starter size from full underwriting

For a diversified investor comfortable with uncertainty, a maximum 0.5%–1.0% exploratory position is defensible. It should have:

  • No automatic averaging down
  • No additions based solely on oversold conditions
  • Predetermined exposure limits
  • Additions tied to cash-flow and operating evidence

For a conservative investor focused on capital preservation, remain entirely on watch until the earnings reconciliation improves.

4. Measure acquisitions by per-share economics

Ignore projected adjusted EBITDA as the principal scorecard. Monitor:

  • Realized cash synergies
  • Free cash flow per diluted share
  • Net debt and interest expense
  • Interest coverage
  • Integration cash costs
  • Post-acquisition ROIC
  • Organic growth excluding acquired revenue

Management creates value only if these transactions improve per-share owner earnings and capital returns after all financing and integration costs.


6. Upgrade and Downgrade Triggers

Upgrade toward ADVOCATE

  • Owner earnings sustain at least approximately $3.60 per share
  • Organic volumes and market share stabilize or improve
  • Gross-margin gains survive normalized brand investment
  • Debt declines and interest coverage remains comfortable
  • Acquisition synergies become visible in cash flow
  • ROIC begins moving convincingly above 7.4%
  • Price remains below a conservatively supported intrinsic value

Downgrade toward AVOID

  • Owner earnings fall below $3.00 without a clearly temporary explanation
  • Persistent organic volume or market-share contraction
  • Acquired growth masks deterioration in the core business
  • Leverage rises or interest coverage approaches distress levels
  • Repeated restructuring adjustments fail to translate into cash
  • Management cuts brand investment to preserve reported margins
  • Post-acquisition ROIC deteriorates further

7. Lessons Applied from Prior Decisions

Past assessments correctly emphasized that a high-quality business can still be a poor purchase at the wrong price. They also showed that binary waiting can miss tactical or partial opportunities.

The improved approach is therefore:

  • Do not confuse an oversold rebound with business recovery.
  • Do not demand perfect confirmation before considering any exposure.
  • Use conditional, limited position sizing when uncertainty is high.
  • Require cash-flow evidence before building a full position.
  • Judge valuation against normalized owner earnings, not a questionable headline multiple.
  • Treat price as one trigger among several, never as a substitute for business verification.

McCormick may eventually prove to be a durable compounder available at an attractive price. At present, that is a plausible scenario rather than a sufficiently evidenced conclusion.

Final Stance: WATCH

Scorecard

Overall 3.03 out of 5, weighted as shown.

DimensionWeightScoreWhat it measures
Business Quality30%3.00 / 5High returns, profitability, and Piotroski health support durability.
Valuation Support30%4.00 / 5Blends current price against available intrinsic value anchors and valuation ratios.
Financial Strength20%2.00 / 5Balance-sheet resilience reflects leverage and liquidity staying within safe ranges.
Growth Durability20%2.67 / 5Recent revenue, earnings, and free cash flow growth indicate how durable expansion looks.

The model

Every input behind the value range, so you can check the work or change an assumption and redo it yourself. Computed deterministically from SEC filings (fiscal 2025), updated Oct 4, 2026; the market price was $44.53. Values are estimates, not predictions.

Owner earnings (Buffett)

Discounts owner earnings: the cash the business generates for its owners after the spending needed to keep it running.

Value per share: $16.98 / $24.26 / $26.32 (conservative / base / optimistic)

Starting Owner Earnings$669M
Growth: conservative / base / optimistic (2015–2025)4.1% / 4.1% / 2.5%
Projection10 years
Discount rate8.6%
Terminal growth2.5%
Shares outstanding269M
The history the growth rates come from (15 years)
2011$419M
2012$434M
2013$428M
2014$443M
2015$411M
2016$460M
2017$448M
2018$591M
2019$661M
2020$673M
2021$664M
2022$549M
2023$597M
2024$690M
2025$782M

Free cash flow

Discounts reported free cash flow: operating cash flow minus capital expenditure.

Value per share: −$4.23 / $47.21 / $86.08 (conservative / base / optimistic)

Starting Free Cash Flow$882M
Growth: conservative / base / optimistic (2020–2025)-31.9% / 3.6% / 15.8%
Projection10 years
Discount rate9.4%
Terminal growth4.5%
Shares outstanding269M
The history the growth rates come from (15 years)
2011$230M
2012$325M
2013$347M
2014$353M
2015$443M
2016$479M
2017$609M
2018$627M
2019$736M
2020$770M
2021$484M
2022$329M
2023$910M
2024$600M
2025$694M

Two-stage FCFF (Damodaran)

Projects revenue, operating margin and reinvestment, then discounts free cash flow to the firm at the weighted cost of capital.

Value per share: $11.00 / $12.77 / $14.33 (conservative / base / optimistic)

Starting Damodaran FCFF$727M
Growth: conservative / base / optimistic (2011–2025)1.4% / 4.5% / 6.6%
Projection10 years
Risk-free rate5.28%
Equity risk premium4.15%
Beta1.00
Cost of equity9.43%
After-tax cost of debt3.91%
Equity weight78%
WACC (discount rate)8.20%
Target operating margin (base)13.3%
High-growth stage5 years
Terminal growth2.5%
Shares outstanding269M

This briefing is from Oct 2, 2026. A fresh one re-reads the latest filings and prices; running it takes a free account.

Run a fresh briefing →Get the iPhone app

The Monday letter

One email a week: what great value investors bought and sold, and what we make of it.

Send me the DeepValues Monday letter, one email a week. I can unsubscribe at any time. Information only, not investment advice. Privacy